Influence of steroid therapy and LDL apheresis therapy on proteinuria of kidney disease

Influence of steroid therapy and LDL apheresis therapy on proteinuria of kidney disease - ITPro study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011517

Enrollment

Registered

2013-08-20

Start date

2013-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney disease patients with proteinuria

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Kidney disease patients with proteinuria

Exclusion criteria

Exclusion criteria: malignancy, and hematological, hepatic, and heart diseases

Design outcomes

Primary

Measure	Time frame
Proteinuria (g/dat, g/gCr), renal function(sCr, cystatin C, eGFR, CCr et al), steroid therapy	—

Secondary

Measure	Time frame
Circulating factors related to proteinuria: lipid (LDL, sdLDL et al), inflammation (high-sensitivity CRP, interleukin-6, tumor necrosis factor-alpha, Th1/Th2 et al), oxidative stress (urine L-type fatty acid binding protein, soluble urokinase receptor, malondialdehyde, ST2S, CLCF-1, hemopexin, vitronectin, Flt-1, PAI-1, MCP-1 et al.)	—

Countries

Japan

Contacts

Public ContactYukiko Hasuike

Hyogo College of Medicine Department of Internal Medicine, Division of Kidney and Dialysis

Outcome results